Innovation drives success in Switzerland's biotech scene

Drug Discovery Today

Volumn 10, Issue 20, 2005, Pages 1342-1345

  Whyte, Barry ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA1A INTERFERON; HUMAN GROWTH HORMONE; RECOMBINANT FOLLITROPIN;

BIOINFORMATICS; BIOTECHNOLOGY; DRUG INDUSTRY; ECONOMIC ASPECT; EUROPE; HEALTH; HEALTH CARE; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; INTERNATIONAL COOPERATION; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; SCIENCE; SHORT SURVEY; SWITZERLAND;

ACHIEVEMENT; BIOTECHNOLOGY; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; DRUG INDUSTRY; HUMANS; SWITZERLAND;

EID: 27144450927     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03605-6     Document Type: Short Survey

References (2)

1. Swiss Biotech Report 2005, The New Edition by Ernst & Young/SWX Swiss Exchange/Swiss Biotech Association.
2. Mol A. Tissue engineering of semilunar heart valves: current status and future developments J. Heart Valve Dis. 13 2004 272 280